• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes non-alcoholic fatty liver disease-authors' reply.

作者信息

Buzzetti Elena, Tsochatzis Emmanuel A

机构信息

UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK.

出版信息

Aliment Pharmacol Ther. 2019 Aug;50(3):339. doi: 10.1111/apt.15385.

DOI:10.1111/apt.15385
PMID:31313369
Abstract
摘要

相似文献

1
Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes non-alcoholic fatty liver disease-authors' reply.信函：使用胶原比例面积来量化肝纤维化并预测非酒精性脂肪性肝病的临床结局——作者回复
Aliment Pharmacol Ther. 2019 Aug;50(3):339. doi: 10.1111/apt.15385.
2
Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2019 Aug;50(3):338. doi: 10.1111/apt.15362.
3
Editorial: collagen proportionate area as a prognostic indicator in NAFLD-authors' reply.社论：胶原比例面积作为非酒精性脂肪性肝病的预后指标——作者回复
Aliment Pharmacol Ther. 2019 Jun;49(11):1454-1455. doi: 10.1111/apt.15271.
4
Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply.
Aliment Pharmacol Ther. 2019 Oct;50(7):836-837. doi: 10.1111/apt.15488.
5
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors' reply.信件：非酒精性脂肪性肝病中伴有显著肝纤维化患者的冠状动脉粥样硬化——无创检测领域。作者回复
Aliment Pharmacol Ther. 2021 Jul;54(2):216. doi: 10.1111/apt.16462.
6
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply.社论：在现实世界中，非酒精性脂肪性肝病有多普遍和严重？作者回复。
Aliment Pharmacol Ther. 2020 Jun;51(11):1200-1201. doi: 10.1111/apt.15724.
7
Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' reply.
Aliment Pharmacol Ther. 2023 Jun;57(12):1463-1464. doi: 10.1111/apt.17517.
8
Editorial: collagen proportionate area as a prognostic indicator in NAFLD.
Aliment Pharmacol Ther. 2019 Jun;49(11):1452-1454. doi: 10.1111/apt.15249.
9
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply.
Aliment Pharmacol Ther. 2022 Jul;56(1):182-183. doi: 10.1111/apt.16972.
10
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply.编者按：非酒精性脂肪性肝病患者F3和F4的逐步风险分层——作者回复
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1318-1319. doi: 10.1111/apt.15040.

引用本文的文献

1
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.不同动物模型和人类肝病病因中门静脉高压的不同结构和动力学成分。
Hepatology. 2022 Mar;75(3):610-622. doi: 10.1002/hep.32220. Epub 2021 Dec 20.